title: Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
abstract: BACKGROUND
  The optimal schedule of taxane administration has been an area of active interest in several clinical trials.
  
  
  METHODS
  To evaluate the efficacy and toxicity of carboplatin and weekly paclitaxel combination chemotherapy, a phase II study was conducted for chemo-naïve, advanced non-small cell lung cancer (NSCLC) patients. Patients received paclitaxel 100 mg/m2 on days 1, 8 and 15, and carboplatin with the target dose of area under the curve of 6 on day 1 every 28 days.
  
  
  RESULTS
  Forty patients were enrolled. Overall response rate and survival at one year by intent-to-treat analyses was 35% and 57.5%, respectively. The median survival time was 12.2 months. Twenty-two patients (56%) had grade 3 or greater neutropenia. Grade 3 sensory and motor neuropathy were seen in one patient (3%).
  
  
  CONCLUSIONS
  Carboplatin and weekly paclitaxel combination chemotherapy is an active and feasible regimen for patients with advanced NSCLC.
authors.affiliation: First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
authors.forename: Megumi
authors.initials: M
authors.lastname: Nakadate
authors.forename: Koichi
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Jun
authors.initials: J
authors.lastname: Konishi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kinoshita
authors.forename: Noriaki
authors.initials: N
authors.lastname: Sukoh
authors.forename: Masao
authors.initials: M
authors.lastname: Harada
authors.forename: Kenji
authors.initials: K
authors.lastname: Akie
authors.forename: Shigeaki
authors.initials: S
authors.lastname: Ogura
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishida
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Munakata
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Dosaka-Akita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Isobe
authors.forename: Masaharu
authors.initials: M
authors.lastname: Nishimura
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel